Sonnet Biotherapeutics Holdings/$SONN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Sonnet Biotherapeutics Holdings
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.
Ticker
$SONN
Sector
Primary listing
Employees
13
Headquarters
Website
SONN Metrics
BasicAdvanced
$23M
-
-$5.01
1.05
-
Price and volume
Market cap
$23M
Beta
1.05
52-week high
$19.30
52-week low
$1.08
Average daily volume
2.5M
Financial strength
Current ratio
0.259
Quick ratio
0.18
Total debt to equity
-2.26
Profitability
EBITDA (TTM)
-14.048
Gross margin (TTM)
-76.75%
Net profit margin (TTM)
-1,355.62%
Operating margin (TTM)
-1,405.87%
Effective tax rate (TTM)
-1.18%
Revenue per employee (TTM)
$80,000
Management effectiveness
Return on assets (TTM)
-223.80%
Return on equity (TTM)
6,329.18%
Valuation
Price to revenue (TTM)
9.394
Price to book
-3.8
Price to tangible book (TTM)
-3.8
Price to free cash flow (TTM)
-0.91
Free cash flow yield (TTM)
-109.89%
Free cash flow per share (TTM)
-3.813
Growth
Revenue change (TTM)
1,689.52%
Earnings per share change (TTM)
-70.21%
3-year revenue growth (CAGR)
9.06%
3-year earnings per share growth (CAGR)
-84.34%
SONN News
AllArticlesVideos
Why Is Sonnet BioTherapeutics Stock Trading Higher On Monday?
Benzinga·1 month ago
This stock rockets 260% after $900 million mega crypto deal
Finbold·1 month ago
SONN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Sonnet BioTherapeutics, Inc. Is Fair to Shareholders
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Sonnet Biotherapeutics Holdings stock?
Sonnet Biotherapeutics Holdings (SONN) has a market cap of $23M as of August 26, 2025.
What is the P/E ratio for Sonnet Biotherapeutics Holdings stock?
The price to earnings (P/E) ratio for Sonnet Biotherapeutics Holdings (SONN) stock is 0 as of August 26, 2025.
Does Sonnet Biotherapeutics Holdings stock pay dividends?
No, Sonnet Biotherapeutics Holdings (SONN) stock does not pay dividends to its shareholders as of August 26, 2025.
When is the next Sonnet Biotherapeutics Holdings dividend payment date?
Sonnet Biotherapeutics Holdings (SONN) stock does not pay dividends to its shareholders.
What is the beta indicator for Sonnet Biotherapeutics Holdings?
Sonnet Biotherapeutics Holdings (SONN) has a beta rating of 1.05. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.